Home » Posts tagged with » amyotrophic lateral sclerosis
BrainStorm Cell Therapeutics doses patients in NurOwn phase 3 trial in ALS

BrainStorm Cell Therapeutics doses patients in NurOwn phase 3 trial in ALS

NurOwn phase 3 trial : BrainStorm Cell Therapeutics, a US biotech company engaged in developing adult stem cell therapies for neurodegenerative diseases, has completed the dosing of all the participants in a phase 3 trial of NurOwn (MSC-NTF cells) in amyotrophic lateral sclerosis (ALS). The late-stage trial enrolled nearly 200 participants, who have been randomized […]

Yumanity secures $500m worth deal with Merck to develop therapies for neurodegenerative disorders

Massachusetts-based Yumanity Therapeutics has secured a drug development deal worth up to nearly $500 million with pharma giant Merck to develop new therapies for neurodegenerative disorders. The partnership is set to combine the drug discovery platform of Yumanity Therapeutics with the development and commercialization expertise in neuroscience of Merck. As per the deal, Merck will […]

Continue reading …
Alexion discloses plan for CHAMPION-ALS clinical trial of ULTOMIRIS

Alexion Pharmaceuticals has revealed plans for initiating the CHAMPION-ALS clinical trial, a phase 3 study to evaluate ULTOMIRIS (ravulizumab) for the treatment of amyotrophic lateral sclerosis (ALS). The late-stage clinical trial, which will be held globally by the US pharma company for 50 weeks, will feature nearly 350 adults across a broad patient population. The […]

Continue reading …
CMD enrolls first patient in placebo-controlled ALS trial of CuATSM

Collaborative Medicinal Development (CMD) has enrolled the first patient in a placebo-controlled clinical trial to evaluate the safety and efficacy of CuATSM in patients with Amyotrophic Lateral Sclerosis (ALS). The Australian biotech company plans to enroll a total of 80 patients across four clinical sites in Australia. Amyotrophic Lateral Sclerosis is also known as Motor […]

Continue reading …
CENTAUR clinical trial of AMX0035 : Amylyx says last patient completes last study visit

Amylyx Pharmaceuticals said that the last enrolled patient in the CENTAUR clinical trial, which is evaluating AMX0035 for amyotrophic lateral sclerosis (ALS), has finished the 24 weeks of study treatment. The CENTAUR clinical study is a randomized, double-blind, placebo-controlled phase 2 clinical trial. The primary goals of the mid-stage clinical trial are to assess the […]

Continue reading …
Neuropore gets FDA orphan drug designation for NPT520-34 for ALS

Neuropore Therapies has secured orphan drug designation for NPT520-34 from the US Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS). The California-based biopharma company said that the orphan drug designation will enable the development of NPT520-34 in the treatment of the debilitating medical condition for which there are not many […]

Continue reading …
Apic Bio bags FDA orphan designation for ALS SOD1 gene therapy APB-102

US gene therapy company Apic Bio said that APB-102, its ALS SOD1 gene therapy, has been granted orphan drug designation by the US Food and Drug Administration (FDA). APB-102 is expected to shortly enter into clinical development for the genetic disorder – SOD1 amyotrophic lateral sclerosis (ALS). The orphan designation is given to novel drugs […]

Continue reading …